{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:55:14Z","timestamp":1771480514891,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Quadruple therapy (renin angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists and sodium\/glucose cotransporter type 2 inhibitors [SGLT2i]) has become the current prognostic modifying treatment for heart failure (HF) with reduced ejection fraction (HFrEF). This study aimed to analyse the prescription\u00b4s evolution of this combination therapy, the analysis of each pharmacological group and the differences according to HF subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective analysis of consecutive patients admitted for cardiac decompensation. Inclusion period: from 1-1-2020 to 12-31-2022. Patients with left ventricular ejection fraction\u2009&gt;\u200940% and deceased during admission were excluded. Finally, 602 patients were included. These were divided into: (a) de novo HF without previous heart disease (n:108), (b) de novo with previous heart disease (n:107), and (c) non-de novo (n:387).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over the study time, all pharmacological groups experienced an increase in drugs prescription (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The group with the largest prescription rate increase was SGLT2i (2020:20%, 2021:42.9%, 2022:70.4%; mean increase 47.2%). The discharge rate prescription of quadruple therapy increased progressively (2020:7.4%, 2021:21.1%, 2022:32.5%; mean increase 21.9%). The subgroup with the highest combined prescription in 2022 was de novo with previous heart disease (43.9%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The pharmacological group with the largest prescription\u00b4s rate increase was SGLT2i. The percentage of patients discharged on quadruple therapy has progressed significantly in recent years, although it remains low. The most optimised subgroup at discharge was that of de novo HF with previous heart disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-024-03728-y","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:02:23Z","timestamp":1707901343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction"],"prefix":"10.1186","volume":"24","author":[{"given":"Raquel","family":"L\u00f3pez-Vilella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"DonosoTrenado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja","family":"Guerrero Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"S\u00e1nchez-L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mart\u00ednez Dolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Almenar Bonet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"3728_CR1","unstructured":"Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;1\u2013128."},{"issue":"18","key":"3728_CR2","first-page":"e876","volume":"145","author":"PA - Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of Heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2022;145(18):e876\u201394.","journal-title":"Circulation"},{"key":"3728_CR3","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020 Jul. 11;396(10244):121\u20138.","DOI":"10.1016\/S0140-6736(20)30748-0"},{"issue":"21","key":"3728_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV - McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. DAPA-HF Trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"3","key":"3728_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ejhf.2447","volume":"24","author":"T - Kondo","year":"2022","unstructured":"Kondo T, Jhund PS, McMurray JJV. Drug therapy for heart failure with reduced ejection fraction: what is the \u2018right\u2019 dose? Eur J Heart Fail. 2022;24(3):421\u201330.","journal-title":"Eur J Heart Fail"},{"key":"3728_CR6","doi-asserted-by":"crossref","unstructured":"Kondo T, Jhund PS, McMurray JJV, Esteban-Fern\u00e1ndez A, G\u00f3mez-Otero I, L\u00f3pez-Fern\u00e1ndez S, Santamarta MR, Pastor-P\u00e9rez FJ, Fluvi\u00e0-Brugu\u00e9s P et al. Esteban-Fern\u00e1ndez A, G\u00f3mez-Otero I, L\u00f3pez-Fern\u00e1ndez S, Santamarta MR, Pastor-P\u00e9rez FJ, Fluvi\u00e0-Brugu\u00e9s P; TIDY-HF investigators. Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction. Clin Res Cardiol. 2023 Jun 21. Epub ahead of print.","DOI":"10.1007\/s00392-023-02241-0"},{"issue":"8","key":"3728_CR7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","volume":"21","author":"R - Wachter","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, et al. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21(8):998\u20131007.","journal-title":"Eur J Heart Fail"},{"key":"3728_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ahj.2020.10.071","volume":"232","author":"ZL - Cox","year":"2021","unstructured":"Cox ZL, Collins SP, Aaron M, Hernandez GA, Iii ATM, Davidson BT, et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Am Heart J. 2021;232:116\u201324.","journal-title":"Am Heart J"},{"key":"3728_CR9","unstructured":"De La - P, Donoso Trenado V, Yebra Pimental Brea C, et al. Characteristics and predictors of prognosis after first hospitalisation for heart failure with reduced ejection fraction in a contemporary registry. Communication accepted for the Spanish Society of Cardiology\u2019s Cardiovascular Health Congress; 2023."},{"key":"3728_CR10","doi-asserted-by":"crossref","unstructured":"Malgie J, Clephas PRD, Brunner-La Rocca HP, de Boer RA, Brugts JJ. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Heart Fail Rev. 2023 Jun 14. Epub ahead of print.","DOI":"10.1007\/s10741-023-10325-2"},{"issue":"7","key":"3728_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jacc.2020.12.026","volume":"77","author":"SJ - Greene","year":"2021","unstructured":"Greene SJ, Triana TS, Ionescu-Ittu R, Shi S, Guerin A, DeSouza MM, et al. Patients hospitalized for de novo versus worsening chronic heart failure in the United States. J Am Coll Cardiol. 2021;77(7):1023\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"3728_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12889-019-7934-3","volume":"20","author":"J - Buddeke","year":"2020","unstructured":"Buddeke J, Valstar GB, van Dis I, Visseren FLJ, Rutten FH, den Ruijter HM, et al. Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men. BMC Public Health. 2020;20:36.","journal-title":"BMC Public Health"},{"issue":"1","key":"3728_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","volume":"11","author":"G - Savarese","year":"2023","unstructured":"Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodeg\u00e5rd J, Lund LH, et al. Heart failure drug Treatment-Inertia, Titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail. 2023;11(1):1\u201314.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"3728_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV - McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus Enalapril in Heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"Supl 1","key":"3728_CR15","first-page":"87","volume":"75","author":"BJL - Reynolds","year":"2022","unstructured":"Reynolds BJL, Ferrer CG, Abdala EM, Moreno MB, \u00c1ngel M, Cerpa S, et al. Grado de implementaci\u00f3n del tratamiento fundamental de la insuficiencia cardiaca con fracci\u00f3n de eyecci\u00f3n reducida tras la publicaci\u00f3n de las \u00faltimas gu\u00edas europeas de cardiolog\u00eda. Rev Esp Cardiol. 2022;75(Supl 1):87.","journal-title":"Rev Esp Cardiol"},{"issue":"1","key":"3728_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ancard.2021.05.004","volume":"71","author":"P - Sabouret","year":"2022","unstructured":"Sabouret P, Attias D, Beauvais C, Berthelot E, Bouleti C, Gibault Genty G, et al. Diagnosis and management of heart failure from hospital admission to discharge: a practical expert guidance. Ann Cardiol Angeiol (Paris) febrero de. 2022;71(1):41\u201352.","journal-title":"Ann Cardiol Angeiol (Paris) febrero de"},{"key":"3728_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.amjcard.2023.03.008","volume":"196","author":"R - L\u00f3pez-Vilella","year":"2023","unstructured":"L\u00f3pez-Vilella R, Jover Pastor P, Donoso Trenado V, S\u00e1nchez-L\u00e1zaro I, Barge Caballero E, Crespo-Leiro MG, Mart\u00ednez Dolz L. Almenar Bonet L. Mortality after the First Hospital Admission for Acute Heart failure, De Novo Versus acutely decompensated heart failure with reduced ejection fraction. Am J Cardiol. 2023;196:59\u201366.","journal-title":"Am J Cardiol"},{"issue":"6","key":"3728_CR18","first-page":"457","volume":"7","author":"C Balmforth","year":"2019","unstructured":"Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC: Heart Failure. 2019;7(6):457\u201365.","journal-title":"JACC: Heart Failure"},{"issue":"4","key":"3728_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/00015385.2020.1747178","volume":"76","author":"R - Pranata","year":"2021","unstructured":"Pranata R, Tondas AE, Yonas E, Vania R, Yamin M, Chandra A, Siswanto BB. Differences in clinical characteristics and outcome of de novo heart failure compared to acutely decompensated chronic heart failure - systematic review and meta-analysis. Acta Cardiol. 2021;76(4):410\u201320.","journal-title":"Acta Cardiol"},{"issue":"1","key":"3728_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ejhf.2382","volume":"24","author":"SJ - Greene","year":"2022","unstructured":"Greene SJ, Butler J, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. Eur J Heart Fail. 2022;24(1):227\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"3728_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL - Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"15","key":"3728_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M - Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"3728_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2478\/rjc-2022-0035","volume":"32","author":"AC - Nechita","year":"2022","unstructured":"Nechita AC. Earlier is better. New options for Acute Heart failure: when, who, how much? Romanian J Cardiol. 2022;32(4):167\u201373.","journal-title":"Romanian J Cardiol"},{"key":"3728_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejim.2022.06.008","volume":"104","author":"R - L\u00f3pez-Vilella","year":"2022","unstructured":"L\u00f3pez-Vilella R, Trenado VD, Cervera BG, S\u00e1nchez-L\u00e1zaro I, Bonet LA. Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis. Eur J Intern Med. 2022;104:128\u201330.","journal-title":"Eur J Intern Med"},{"issue":"10367","key":"3728_CR25","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A - Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938\u201352.","journal-title":"Lancet"},{"issue":"6","key":"3728_CR26","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1002\/ehf2.12978","volume":"7","author":"S - Straw","year":"2020","unstructured":"Straw S, McGinlay M, Relton SD, Koshy AO, Gierula J, Paton MF, et al. Effect of disease-modifying agents and their association with mortality in multi\u2010morbid patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2020;7(6):3859\u201370.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"3728_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA - Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"key":"3728_CR28","doi-asserted-by":"crossref","unstructured":"Kurdi H, Shah P, Barker S, Harris D, Dicken B, Edwards C, Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure. Br J Cardiol., Jensen J, Poulsen MK, Petersen PW, Gerdes B, Rossing K, Schou M et al. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study. ESC Heart Fail. junio de 2023;10(3):1745-56.","DOI":"10.1002\/ehf2.14324"},{"issue":"4","key":"3728_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cardfail.2021.11.010","volume":"28","author":"M - Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, Devore AD, et al. Projected clinical benefits of implementation of SGLT-2 inhibitors among Medicare beneficiaries hospitalized for heart failure. J Card Fail Abril de. 2022;28(4):554\u201363.","journal-title":"J Card Fail Abril de"},{"issue":"7","key":"3728_CR30","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/biomedicines10071721","volume":"10","author":"P - Scicchitano","year":"2022","unstructured":"Scicchitano P, Iacoviello M, Massari F, De Palo M, Caldarola P, Mannarini A, et al. Optimizing therapies in Heart failure: the role of Potassium Binders. Biomedicines. 2022;10(7):1721.","journal-title":"Biomedicines"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-03728-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-03728-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-03728-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:04:46Z","timestamp":1707901486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-03728-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3728"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-03728-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"12 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the hospital\u2019s Biomedical Research Ethics Committee and followed the ethical principles for medical research on human subjects as defined by the Declaration of Helsinki. The Ethics Committee granted the study exemption from informed consent for non-deceased patients, due to the observational, non-interventional and retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}